Lisata Therapeutics, Inc. (LSTA) Free cash flow 2015–2024
Lisata Therapeutics, Inc. (LSTA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$16.0MFY2024 · since FY2015: -$24.8M → -$16.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$16.0M | +17.5% |
| FY2023 | -$19.4M | +3.4% |
| FY2022 | -$20.0M | +6.6% |
| FY2021 | -$21.5M | +3.8% |
| FY2020 | -$22.3M | -152.2% |
| FY2019 | -$8.8M | +53.2% |
| FY2018 | -$18.9M | +6.2% |
| FY2017 | -$20.1M | +4.2% |
| FY2016 | -$21.0M | +15.2% |
| FY2015 | -$24.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More LSTA financial trends
LSTA RevenueLSTA Net incomeLSTA Net marginLSTA Gross profitLSTA Gross marginLSTA Operating incomeLSTA Operating marginLSTA Operating cash flowLSTA Capital expendituresLSTA Return on equityLSTA Stock buybacksLSTA Dividends paidLSTA Total assetsLSTA Total liabilitiesLSTA Shareholders’ equityLSTA overview →